KRAS and neoplasm: While our current study revealed the anti‐tumor activity of the highly specific ADAM17 inhibitor, A17pro, as a monotherapy in various preclinical mutant KRAS LAC models, one of which was a PDX, there is now the need to evaluate the efficacy of A17pro in combination with existing chemotherapeutics (e.g., cisplatin) (Hirsch et al, 2017).